复宏汉霖:截至2024年12月31日止年度,本集团总收入约为人民币5,724.4百万元,同比增长约6.1%。研发支出约为人民币1,840.5百万元,较上年增加406.9百万元。盈利总额约为人民币820.5百万元,较上年增加274.5百万元。董事会不建议派发末期股息。核心产品汉曲优 已惠及超过24万名患者,并在美国和加拿大获得批准用于乳腺癌及胃癌治疗。汉斯状 在中国市场已惠及超10万名患者,并获得新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.